Gleolan to help surgeons find ovarian cancer during surgery
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 3 study tests whether Gleolan (a medicine given before surgery) helps doctors better see ovarian, fallopian tube, or peritoneal cancer during an operation. It may help improve how well surgeons can remove visible tumor tissue during planned surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian cancer (newly found or coming back), or strong suspicion of it, and you are planning planned surgery to remove as much tumor as possible.
- You had a scan (MRI, PET, or CT) within 30 days showing suspected tumor or recurrence that surgery is planned to treat.
- You are a woman age 18 or older.
- You need to be healthy enough for surgery, including normal blood/organ function tests and bone marrow function.
- You must understand the consent form and be willing to sign it in writing (English or Spanish, with help if needed).
- If you could get pregnant, you must use very reliable birth control starting with the Gleolan medicine and for at least 42 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This laboratory study uses ovarian cancer fluid collected during surgery to test possible new treatments on cancer and immune cells. It may help researchers find better treatment options in ovarian cancer.
This study uses lab testing to create a “map” of ovarian cancer cells one cell at a time, to better understand the disease. It likely helps researchers learn which cell types are involved, using samples collected around your surgery.
This study tests whether monitoring a tumor marker called KELIM can help doctors decide the best time for surgery in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants first receive chemotherapy to shrink tumors, then have surgery either at a planned time or later based on how the tumor marker changes.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.